key: cord-0261089-eugetpt3 authors: Suh, I. B.; Lim, J.; Kim, H. S.; Rhim, G.; Kim, H.; Lee, S.-M.; Park, H.-s.; Song, H. J.; Hong, M.; Shin, G. S.; Kim, M. J. title: Development and Evaluation of AccuPower(R) COVID-19 Multiplex Real-Time RT-PCR Kit and AccuPower(R) SARS-CoV-2 Multiplex Real-Time RT-PCR Kit for SARS-CoV-2 Detection in Sputum, NPS/OPS, Saliva and Pooled Samples date: 2021-11-24 journal: nan DOI: 10.1101/2021.11.21.21264927 sha: 6875aa42b3bc226da9f8f6e4cb8143464280eade doc_id: 261089 cord_uid: eugetpt3 Rapid and accurate detection of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is essential for the successful control of the current global COVID-19 pandemic. The real-time reverse transcription polymerase chain reaction (Real-time RT-PCR) is the most widely used detection technique. This research describes the development of two novel multiplex real-time RT-PCR kits, AccuPower (R) COVID-19 Multiplex Real-Time RT-PCR Kit (NCVM) specifically designed for use with the ExiStation 48 system (comprised of ExiPrep 48 Dx and Exicycler 96 by BIONEER, Korea) for sample RNA extraction and PCR detection, and AccuPower (R) SARS-CoV-2 Multiplex Real-Time RT-PCR Kit (SCVM) designed to be compatible with manufacturers` on-market PCR instruments. The limit of detection (LoD) of SCVM was 2 copies/{micro} L and the LoD of the NCVM was 120 copies/mL for both the gene and the SARS-CoV-2 gene (N gene and RdRp gene). The AccuPower (R) kits demonstrated high precision with no cross reactivity to other respiratory-related microorganisms. The clinical performance of AccuPower (R) kits was evaluated using the following clinical samples: sputum and nasopharyngeal/oropharyngeal swab (NPS/OPS) samples. Overall agreement of the AccuPower (R) kits with a Food and Drug Administration (FDA) approved emergency use authorized commercial kit (STANDARD M nCoV Real-Time Detection kit, SD BIOSENSOR, Korea) was above 95% (Cohen`s kappa coefficient [≥] 0.95), with a sensitivity of over 95%. The NPS/OPS specimen pooling experiment was conducted to verify the usability of AccuPower (R) kits on pooled samples and the results showed greater than 90% agreement with individual NPS/OPS samples. The clinical performance of AccuPower (R) kits with saliva samples was also compared with NPS/OPS samples and demonstrated over 95% agreement (Cohen`s kappa coefficient > 0.95). This study shows the BIONEER NCVM and SCVM assays are comparable with the current standard confirmation assay and are suitable for effective clinical management and control of SARS-CoV-2. Coronavirus disease 2019 was first detected in Wuhan, China in 2019, 58 and its outbreak has spread to other countries which led to a global pandemic (1). The virus 59 that causes COVID-19 was named severe acute respiratory syndrome coronavirus 2 (SARS-60 CoV-2), which is the seventh known coronavirus that can infect humans (2). According to 61 World Health Organization (WHO), as of June 30, 2021, approximately 181 million people 62 were confirmed with SARS-CoV-2 infection, and 3.9 million were dead world-wide. (https://covid19.who.int/). 64 The key strategy for controlling outbreaks of COVID-19 is early and accurate is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted November 24, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 -4 -Real-Time RT-PCR Kit (Cat No. NCVM-1111, BIONEER, Korea) and AccuPower ® SARS- 77 CoV-2 Multiplex Real-Time RT-PCR Kit (Cat No. SCVM-2112, BIONEER, Korea) , were used 78 in this study to detect the three viral genes of SARS-CoV-2 (RdRp gene, E gene, and N gene). 79 The NCVM is a premixed product that is specifically designed to be used with the is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint probes attach specific sequences, which distinctively appear in the SARS-CoV-2 gene. . CC-BY-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted November 24, 2021. ; https://doi.org/10.1101 doi: medRxiv preprint -6 -TaqMan ® probe contains the fluorescence in the 5' end and the quencher in the 3' end so the 110 fluorescence is not released in the usual state. The fluorescence signal is emitted as the 5'-3' 111 exonuclease in DNA polymerase detaches from the probe, while the fluorescence and the 112 quencher detach during PCR. The RNA presence can be detected by fluorescence signals. The NCVM is a freeze-114 dried premixed product for use only with the ExiStation™48 system (ExiPrep™48 Dx & 115 Exicycler™96). The SCVM is a master-mix product, which can be used with various PCR 116 instruments. PCR reaction of AccuPower ® kits was conducted according to each manufacturer's 117 protocol. Analytical Performance Evaluation 120 The LoD, cross-reactivity, and precision were analyzed using the AccuPlex™ SARS- is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted November 24, 2021. ; https://doi.org/10.1101/2021.11.21.21264927 doi: medRxiv preprint -7 -The LoD measurement was performed, following the CLSI guideline EP17-A2 (6). The LoD for the E gene and the SARS-CoV-2 gene were determined by measuring the RNA 132 level in the AccuPlex™ SARS-CoV-2 Verification Panel (Virus-Like Particles, SeraCare, USA) 133 using the NCVM, and the SARS-Related Coronavirus 2 (Isolate USA-WA1/2020) using the 134 SCVM. The AccuPlex™ SARS-CoV-2 Verification Panel were serially diluted to 6 136 concentration levels (240, 200, 160, 120, 80 , 40 copies/mL) for the NCVM testing. Each 137 dilution was tested in total 40 replicates, 20 replicates per lot, 2 lots. The SARS-Related Coronavirus 2 (Isolate USA-WA1/2020) also were serially diluted to 6 concentration levels (6, 139 5, 4, 3, 2, 1 copies/μL) for the SCVM testing. Each dilution was tested in total 60 replicates, 140 20 replicates per lot, 3 lots. Both LoD tests were performed on the Exicycler™96 (BIONEER, 141 Korea) and determined using hit-rate analysis as the concentration at the lowest dilution that 142 can be detected with >95% probability. The cross-reactivity test was performed according to WHO EUL guidance (7) and 146 Food and Drug Administration (FDA) guideline (8). The specificity of AccuPower ® kits for 147 SARS-CoV-2 detection was evaluated by in silico analysis followed by testing the SARS-CoV-148 2 control with respiratory disease-related viruses and bacteria genes (concentration above 149 1.0x10 6 copies/mL). Altogether, 29 respiratory disease-related microorganisms were tested 150 using the NCVM and 38 were tested using the SCVM. The cross-reactivity test was performed 151 using the Exicycler™96. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted November 24, 2021. ; https://doi.org/10.1101/2021.11.21.21264927 doi: medRxiv preprint -8 - Precision 154 The repeatability was tested according to the CLSI Guideline EP05-A3 (9) and EP15-155 A3 (10). The repeatability of the AccuPower ® kits performance was evaluated by intra-assay 156 and inter-assay variations at different concentrations of NPS/OPS, sputum, and saliva samples. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted November 24, 2021. ; https://doi.org/10.1101/2021.11.21.21264927 doi: medRxiv preprint -9 - Clinical Performance Evaluation Test 175 The clinical performance of AccuPower ® kits was evaluated by comparing the PCR is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted November 24, 2021. ; https://doi.org/10.1101/2021.11.21.21264927 doi: medRxiv preprint -10 - A 5-pool test on NPS/OPS samples was performed to evaluate the performance of the The AccuLoader ™ (BIONEER, Korea) which was designed to automatically load 208 samples into a reaction well was used to pool NPS/OPS specimens to reduce human error and 209 carry-over/cross-over contamination (Fig 2) . A tablet PC connected to the AccuLoader ™ 210 controls the instrument, which consists of a barcode reader, a contamination shield cover, and is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted November 24, 2021. ; https://doi.org/10.1101/2021.11.21.21264927 doi: medRxiv preprint -11 -sample in the pool. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted November 24, 2021. ; https://doi.org/10.1101/2021.11.21.21264927 doi: medRxiv preprint -13 - The LoD of NCVM was 120 copies/mL for the E gene (hit rate = 95%) and 120 247 copies/mL for the SARS-CoV-2 gene (hit rate = 95%) using the ExiStation ™ 48 System 248 (ExiPrep™48 Dx & Exicycler™96). The LoD of SCVM was 2 copies/μL for the E gene (hit 249 rate = 95%), 2 copies/μL for the SARS-CoV-2 gene (hit rate = 95%) using the ExiCycler ™ 96. ( is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The repeatability of the AccuPower ® kits was analyzed by comparing Ct values of the 271 PCR result within runs, between runs, and between days in each matrix at each concentration. between-day, and total precision. (S1 Table) . is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint Cohen's kappa coefficient was 0.97 (Table 5) . . CC-BY-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted November 24, 2021. Pooled samples were prepared as described above (S2 Table) . Samples were then 323 tested individually using the AccuPower ® kits and the reference kit. The test showed 100% 324 positive and negative agreement of the AccuPower ® kits with the reference kit. The clinical 325 performance of the AccuPower ® kits was also tested using in 5-pooled samples and evaluated 326 by comparing the PCR results from the AccuPower ® kits to that of the reference kit. For NCVM, 327 the positive percentage agreement was 93.30% (95% CI: 77.93% -99.18%) and the negative 328 percentage agreement was 100.00% (95% CI: 88.43% -100.00%) with the reference test of 329 pooled samples. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted November 24, 2021. ; https://doi.org/10.1101/2021.11.21.21264927 doi: medRxiv preprint -19 -was 1.65 higher than the average Ct value of individual samples in the E gene and 1.90 higher 335 in the SARS-CoV-2 gene (Fig 3.A) . The degree of association between the Ct value of 336 individual samples and the Ct value of pooled samples was analyzed by regression analysis 337 and expressed as y=0.887x+4.885, R 2 =0.9700 in the E gene and y=0.983x+2.375, R 2 =0.9955 338 in the SARS-CoV-2 gene (Fig 3.B) . Table) . is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted November 24, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The results indicate the adequacy of the AccuPower ® kits for the use with saliva samples (Table 391 7). The scatter plots of Ct values in paired NPS/OPS and saliva specimens were analyzed 393 for each AccuPower ® kit (Fig 4.B) . is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted November 24, 2021. ; https://doi.org/10. 1101 A pneumonia outbreak 488 associated with a new coronavirus of probable bat origin The proximal origin of 490 SARS-CoV-2 Detection of 492 SARS-CoV-2 RNA by multiplex RT-qPCR Comparison of seven commercial RT-PCR diagnostic kits for COVID-19 Promising methods for detection of novel 497 coronavirus SARS-CoV-2 CLSI guideline EP17-A2. Evaluation of Detection Capability for Clinical 499 Laboratory Measurement Procedures. Clinical and Laboratory Standards Institute 2nd edition CLSI. CLSI guideline EP07-A2. Interference Testing in Clinical Chemistry. Clinical 502 and Laboratory Standards Institute Policy for Coronavirus Disease-2019 Tests During the Public Health Emergency 504 (Revised) -Immediately in Effect Guidance for Clinical Laboratories, Commercial 505 Manufacturers, and Food and Drug Administration Staff CLSI. CLSI guideline EP05-A3. Evaluating Quantitative Measurement Precision CLSI guideline EP15-A3. User Verification of Precision and Estimation Comparison of Two Commercial Platforms and a Laboratory-Developed Test for Detection 512 of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) RNA Breakthrough Infections with SARS-CoV-2 Variants Development of 517 multiplex real-time RT-PCR assay for the detection of SARS-CoV-2 Development of a New Multiplex Real-Time RT-PCR Assay for 520 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Detection Kits for SARS-CoV-2 Real-Time Reverse-Transcription Polymerase Chain Reaction Approved 524 by Emergency-Use-Authorization in Korea Sensitivity evaluation of 2019 novel 526 coronavirus (SARS-CoV-2) RT-PCR detection kits and strategy to reduce false negative Saliva is more 529 sensitive than nasopharyngeal or nasal swabs for diagnosis of asymptomatic and mild COVID-530 19 infection Analytical and Clinical Evaluation of The analytical performance of two AccuPower ® kits (NCVM as the premix type and 420 SCVM as the master mix type) was evaluated. The NCVM was designed to be used on a closed 421 system (ExiStation™48 system) to provide full automation and contamination-free and error-422 free results. The LoD of the NCVM was 120 copies/mL for the E gene and the SARS-CoV-2 423 gene as determined by the ExiStation™48 system. On the other hand, the SCVM was designed Table) . Cross-reactivity was tested with 29 respiratory disease-related viruses and bacteria 432 genes were performed for the NCVM, and with 38 for the SCVM, respectively. The results showed that there was no detectable cross-reactivity in AccuPower ® kits, Precision of the two 434 AccuPower ® kits was evaluated and the results showed high within-run, between-run, between-435 day, and total precision. This study provides the data to support the usability of the AccuPower ® kits for the is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintThe copyright holder for this this version posted November 24, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintThe copyright holder for this this version posted November 24, 2021. ; https://doi.org/10.1101/2021.11.21.21264927 doi: medRxiv preprint -26 -indicated high sensitivity and specificity (>95%) (S5 Table) . Thus, it may be suggested that 466 AccuPower ® kits have equivalent clinical sensitivity with Allplex™ 2019-nCoV Assay. In conclusion, this study describes the successful development of two multiplex real- is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintThe copyright holder for this this version posted November 24, 2021. ; https://doi.org/10.1101/2021.11.21.21264927 doi: medRxiv preprint -27 - . CC-BY-ND 4.0 International license It is made available under a perpetuity.is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintThe copyright holder for this this version posted November 24, 2021. ; https://doi.org/10.1101/2021.11.21.21264927 doi: medRxiv preprint 532 "AccuPower SARS-CoV-2 Multiplex RT-PCR kit (Bioneer, South Korea)" and "Allplex 2019-533 . CC-BY-ND 4.0 International license It is made available under a perpetuity.is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintThe copyright holder for this this version posted November 24, 2021. ; https://doi.org/10.1101/2021.11.21.21264927 doi: medRxiv preprint -30 -S3 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintThe copyright holder for this this version posted November 24, 2021. ; https://doi.org/10. 1101